Briggs Morrison trades lead role in AstraZeneca R&D for the helm of tiny Syndax
15 June 2015
Last week, Briggs Morrison was the head of late-stage development and chief medical officer at AstraZeneca with responsibility for leading the turnaround at one of the world's biggest pharma pipelines with thousands of staffers, dozens of clinical-stage programs and a budget that's in the billions. This week, he's moving to a new job as CEO of Syndax Pharmaceuticals, a small biotech based in Waltham, MA, that has a staff of 20, counts its research budget in the millions and has a pipeline with one drug, the histone deacetylase (HDAC) inhibitor entinostat.
15 June 2015
Syndax Pharmaceuticals, Inc., a privately held oncology company, announced today that Briggs W. Morrison, M.D. is joining the Company as Chief Executive Officer and a member of the Board of Directors, and that Michael A. Metzger is joining the Company as President and Chief Operating Officer. Dr. Morrison joins Syndax from AstraZeneca, where he was Executive Vice President, Global Medicines Development and Chief Medical Officer.
Atlas Genetics participates in £1.5m Grant Funding Award
11 June 2015
Atlas Genetics Ltd (“Atlas” or the “Company”), the ultra-rapid ‘test and treat’ molecular diagnostics company, today announces a collaboration with St George’s, University of London to develop and evaluate DNA-based point of care tests which can simultaneously detect both infection and antibiotic resistance in a patient within the same clinical visit.
Suprachoroidal injection of triamcinolone acetonide for uveitis proves promising
11 June 2015
Patients with noninfectious uveitis who were treated with a single suprachoroidal injection of triamcinolone acetonide in a 6-month phase I/II clinical trial exhibited improvements in best-corrected visual acuity (BCVA), said investigator Debra A. Goldstein, MD.
11 June 2015
Celtaxsys, a clinical stage drug development company focused on advancing care for patients suffering from inflammatory diseases, including those with rare and orphan inflammatory diseases, announced today data from Phase 1 clinical trials of CTX-4430 will be presented at the 2015 Meeting of the European Cystic Fibrosis Society in Brussels on Friday, Jun 12, 2015.
08 June 2015
Celtaxsys, a clinical stage drug development company focused on developing novel therapies for patients suffering from inflammatory diseases, today announced the successful completion of a $40M Series D financing led by Domain Partners VIII. Additional investors in the financing include Lumira Capital, RMI Partners, Masters Capital Management and the Georgia Research Alliance Venture Fund.
02 June 2015
Celtaxsys, a clinical stage drug development company focused on advancing care for patients suffering from inflammatory diseases, including those with rare and orphan inflammatory diseases, announced today that it has received a development award for $5 million from Cystic Fibrosis Foundation Therapeutics, Inc. ("CFFT"), the non-profit drug discovery and development affiliate of the Cystic Fibrosis Foundation The development award will help support a Phase 2 clinical trial of the Company's lead development candidate, a once daily, oral anti-inflammatory drug CTX-4430 in adults with cystic fibrosis ("CF"). CTX-4430 is a selective inhibitor of Leukotriene A4 Hydrolase that targets re-balancing of a patient's over activated inflammatory response without increasing susceptibility to infection. CTX-4430 has been granted orphan status for CF in both the US and the EU.
Epic Sciences Expands Silicon Valley Bank Credit Facility
01 June 2015
Epic Sciences, Inc., a private diagnostics company that designs and develops products and offerings to personalize and advance the treatment and management of cancer, announced today that it has expanded the available credit under its existing credit facility with Silicon Valley Bank (SVB). The amended agreement increases the available capacity of the facility from $5 million to $15 million and has extended the maturity by 27 months to April 1, 2019.
18 May 2015
Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative epilepsy and other neuropsychiatric therapeutics, announced that Gail M. Farfel, Ph.D., Chief Clinical and Regulatory Officer of Marinus, presented clinical data on ganaxolone in drug-resistant pediatric epilepsies at the Antiepileptic Drug and Device Trials (AED) XIII conference on Friday, May 15, 2015.
New glaucoma devices bring new dimension of treatment
18 May 2015
The loss of visual acuity associated with glaucoma may be an indirect result of increased IOP. But increased IOP is rarely the result of excessive aqueous production. It is usually an insufficiency in aqueous outflow.
14 March 2024
26 February 2024
NovaMedica team wishes you a Merry Christmas and a Happy New Year!
26 December 2023
The overall mortality rate of the population in Russia decreased by 7% in 2023
28 March 2024
Russia to collaborate with Hungary and Serbia in nuclear medicine
28 March 2024
Researchers propose novel test for pyrogen detection
27 March 2024
Parkinson’s infusion treatment demonstrates advantage over oral delivery
27 March 2024